Ocular Signs Correlate Well with Disease Severity and Genotype in Fabry Disease

Ocular signs in Fabry disease have generally been regarded to be primarily of diagnostic value. We explored whether ocular findings, alone or in particular in combination with the α-galactosidase A gene mutation, have predictive value for disease severity. Data from the Fabry Outcome Survey (FOS), a large, global database sponsored by Shire, were selected for adult patients who had undergone ophthalmological examination. Three ocular signs were assessed: cornea verticillata, tortuous conjunctival and/or retinal vessels, and cataract. Fabry disease severity was measured using FOS Mainz Severity Score Index and modifications thereof. Ophthalmological data were available for 1203 (699 female, 504 male) adult patients with eye findings characteristic of Fabry disease in 55.1%. Cornea verticillata had a similar distribution in women (51.1%) and men (50.8%), whereas tortuous vessels and Fabry cataract were somewhat more frequent in men than in women. Patients with cornea verticillata, selected as the principal ocular sign for this study, had more severe disease (median score, 20.0) versus those without ocular signs (11.0; P<0.001). This finding could be confirmed by applying age adjusted severity scores. Moreover, the prevalence of cornea verticillata was significantly higher in patients with null (male, 76.9%; female, 64.5%) and missense (male, 79.2%; female, 67.4%) mutations versus mild missense (male, 17.1%; female, 23.1%) and the p.N215S (male, 15.0%; female, 15.6%) mutations (P<0.01). Our analyses show a correlation between the prevalence of ocular changes in Fabry disease and disease severity. Consequently, information on ocular findings and α-galactosidase A gene mutation may help assess the risk for more severe Fabry disease. These observed findings are of notable clinical importance, as Fabry disease is characterized by high clinical course variability and only weak genotype-phenotype correlation at the individual patient level. Further confirmatory studies are needed.

[1]  S. Brodie,et al.  Inner macular hyperreflectivity demonstrated by optical coherence tomography in niemann-pick disease. , 2013, JAMA ophthalmology.

[2]  M. Motwani,et al.  Enzyme replacement therapy improves cardiac features and severity of Fabry disease. , 2012, Molecular genetics and metabolism.

[3]  U. Ramaswami,et al.  Age adjusting severity scores for Anderson-Fabry disease. , 2010, Molecular genetics and metabolism.

[4]  Shih-Jen Chen,et al.  Enzyme assay and clinical assessment in subjects with a Chinese hotspot late-onset Fabry mutation (IVS4 + 919G→A) , 2010, Journal of Inherited Metabolic Disease.

[5]  M. Browning,et al.  Ocular manifestations of Fabry disease within in a single kindred. , 2010, Optometry.

[6]  U. Ramaswami,et al.  Fabry disease in children: correlation between ocular manifestations, genotype and systemic clinical severity , 2010, British Journal of Ophthalmology.

[7]  A. Gal,et al.  A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease , 2009, Genetics in Medicine.

[8]  S. Feriozzi,et al.  Enzyme replacement therapy with agalsidase alfa in a cohort of Italian patients with Anderson–Fabry disease: testing the effects with the Mainz Severity Score Index , 2008, Clinical genetics.

[9]  N. Samiy Ocular features of Fabry disease: diagnosis of a treatable life-threatening disorder. , 2008, Survey of ophthalmology.

[10]  D. Joly,et al.  Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature , 2007, International journal of clinical practice.

[11]  A. Mehta,et al.  Ocular manifestations of Fabry’s disease: data from the Fabry Outcome Survey , 2006, British Journal of Ophthalmology.

[12]  C. Wanner,et al.  Clinical benefit of enzyme replacement therapy in Fabry disease. , 2006, Kidney international.

[13]  K. Nicholls,et al.  Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre , 2005, Clinical & experimental ophthalmology.

[14]  C. Barr,et al.  Vitreous opacities and retinal vascular abnormalities in Gaucher disease. , 2004, Archives of ophthalmology.

[15]  A. Schwarting,et al.  The Mainz Severity Score Index: a new instrument for quantifying the Anderson–Fabry disease phenotype, and the response of patients to enzyme replacement therapy , 2004, Clinical genetics.

[16]  O. Gabrielli,et al.  Fabry disease: molecular studies in Italian patients and X inactivation analysis in manifesting carriers , 2003, Journal of medical genetics.

[17]  C. Orssaud,et al.  Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients , 2003, Ophthalmic genetics.

[18]  K. Macdermot,et al.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males , 2001, Journal of medical genetics.

[19]  D. F. Moore,et al.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial. , 2001, JAMA.

[20]  O. Tsutsumi,et al.  CORNEAL FINDINGS IN A FOETUS WITH FABRY'S DISEASE , 1984, Acta ophthalmologica.

[21]  R. Desnick,et al.  The ocular manifestations in Fabry's disease. , 1979, Archives of ophthalmology.

[22]  Charles A. Garcia,et al.  Ocular findings in mannosidosis. , 1976, American journal of ophthalmology.

[23]  G. Spaeth,et al.  Fabry's disease. Its ocular manifestations. , 1965, Archives of ophthalmology.

[24]  A. Sodi,et al.  Ophthalmological manifestations of Fabry disease , 2006 .

[25]  A. Mehta,et al.  Ophthalmological manifestations of Fabry disease -- Fabry Disease: Perspectives from 5 Years of FOS , 2006 .

[26]  A. Mehta,et al.  Diagnosis of Fabry disease: the role of screening and case-finding studies -- Fabry Disease: Perspectives from 5 Years of FOS , 2006 .